QCLS NASDAQ
Q/C Technologies, Inc.
1W: -13.8%
1M: -60.8%
3M: -80.6%
YTD: -82.3%
1Y: -82.2%
$0.75
-0.03 (-3.52%)
Weekly Expected Move ±73.5%
$-0
$0
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-03-19
Earliest Filing
2025-12-09
Latest Filing
partner: 8
acquirer: 3
target: 2
Counterparties (Filed by QCLS)
13 relationshipsCompanies named in QCLS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Q/C Technologies, Inc. | QCLS | acquirer | Company entering into consulting services agreement and issuing warrants and restricted stock | 2025-12-09 | View |
| Ocean Avenue Holdings LLC | — | partner | Consultant providing services and receiving warrants and restricted stock | 2025-12-09 | View |
| TNF Pharmaceuticals, Inc. | — | target | Company issuing shares in a stock purchase agreement | 2024-10-07 | View |
| Prevail Partners, LLC | — | acquirer | Investor purchasing common stock from the Company | 2024-10-07 | View |
| Prevail InfoWorks, Inc. | — | partner | Affiliate of Prevail Partners providing technology and services for a clinical trial | 2024-10-07 | View |
| Cystron LLC | — | target | Target of Akers' acquisition of 100% membership interests prior to contribution to Oravax | 2021-03-19 | View |
| Premas Biotech PVT Ltd | — | partner | Licensor of vaccine platform technology to Cystron | 2021-03-19 | View |
| Oravax Medical, Inc | — | partner | Entity receiving assets from Cystron and issuing stock to Akers and Oramed | 2021-03-19 | View |
| Oramed Ltd | ORMP | partner | Licensor of oral delivery technology to Oravax and cash contributor | 2021-03-19 | View |
| Oramed Pharmaceuticals, Inc | ORMP | partner | Licensor of oral delivery technology to Oravax and cash contributor | 2021-03-19 | View |
| MyMD Pharmaceuticals, Inc | — | acquirer | Proposed acquirer of Akers Biosciences, Inc. in the MYMD Merger | 2021-03-19 | View |
| XYZ Merger Sub Inc | — | partner | Wholly-owned subsidiary of Akers used as merger vehicle | 2021-03-19 | View |
| VStock Transfer LLC | — | partner | Rights Agent for the Company's Rights Agreement | 2021-03-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-18 | Material Agreement; Officer/Director Change; Regulation FD; Exhibits | Agreement | View |
| 2026-09-11 | Termination of Agreement; Officer/Director Change; Exhibits | View | |
| 2026-07-02 | Termination of Agreement; Other Events | View | |
| 2026-03-13 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2026-01-23 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-12-09 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-11-14 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-10-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2025-09-26 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-09-10 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders; Amend | Agreement | View |
| 2025-09-05 | Financial Statements and Exhibits | View | |
| 2025-09-02 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Unregistered | Agreement | View |
| 2025-06-06 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-05-09 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-04-11 | Shareholder Nominations | View | |
| 2025-03-21 | Notice of Delisting or Transfer | View | |
| 2025-03-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-26 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2024-10-07 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR